The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
Robust specificity data mark Roche’s serological test out as a major competitor.
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.